Prurigo nodularis

OLYMPIA 2 (NCT04501679) was a phase 3, multicentre, double-blind study that investigated the IL-31 inhibitor nemolizumab for the treatment of prurigo nodularis in adults. touchDERMATOLOGY were delighted to speak with Prof. Adam Reich (University of Medicine, Wroclaw, Poland) around his analysis of OLYMPIA 2, looking at improvements in pain and patient reported outcomes. The abstract ‘Nemolizumab modulates prurigo nodularis-associated skin pain and markedly improves patient reported outcomes in patients with moderate-to-severe prurigo nodularis in a phase 3 study (OLYMPIA 2).' (Abstract N°: 4147) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What is the mechanism of action and rationale for investigating nemolizumab in prurigo nodularis? (0:18) Could you describe the aims and design of the phase 3 OLYMPIA 2 study, and how well the key endpoints were met? (0:50) What additional outcomes were investigated in your analysis of OLYMPIA 2 and how well were they met? (1:29) What will be the next steps in the clinical development of  nemolizumab? (2:05) Disclosures: Adam Reich discloses receiving grant/research support from Abbvie, Anaptys, BMS, Dice, Eli Lilly, Galderma, Incyte, Jannsen, Medac, Novartis, Pfizer, Regeneron, Trevi Therapeutics, and UCB; serving on advisory boards for Abbvie, Galderma, Leo Pharma, Sanofi, Novartis, and Eli Lilly. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Atopic dermatitis and prurigo nodularis are type 2 inflammatory skin diseases with intense pruritis. Both share mechanisms of disease, including inflammation with the role of type 2 cytokines in driving itch. We were delighted to speak to Expert Faculty member Dr. Raj Chovatiya (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the burden of itch and its impact on quality of life, dupilumab’s recent approval and its impact on the treatment landscape. Questions Could you describe the burden of itch and the impact this has on patient quality of life? (0:17) What impact has the approval of dupilumab had on the treatment paradigm for pruritic diseases? (0:56) How do atopic dermatitis (AD) and prurigo nodularis (PN) differ in presentation, despite sharing a similar pathology? (1:29) Aside from relieving itch, what other benefits are associated with targeting IL-4 and IL-13 signalling in AD and PN? (2:13) What are the next steps to achieving disease control in inflammatory skin diseases? (2:42) Disclosures: Raj Chovatiya discloses advising, consulting, and/or speaking for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, and UCB. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

LIBERTY-PN PRIME (NCT04183335) was a randomised, double-blind, placebo-controlled phase 3 trial, investigating dupilumab for the treatment of prurigo nodularis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) to discuss the aims, design and eligibility criteria of the phase 3 study and the findings in terms of itch […]